Plexxikon

Plexxikon is an American drug discovery company based in Berkeley, California. It was co-founded in 2001 by Joseph Schlessinger of Yale University, and Sung-Hou Kim of the University of California, Berkeley.

Plexxikon
IndustryBiotechnology
FateAcquired by the Daiichi Sankyo
Founded2001 (2001)
FounderJoseph Schlessinger
Defunct2011 (2011)
HeadquartersBerkeley, California, United States.

It uses a proprietary structural biology-based platform called Scaffold-Based Drug Discovery to build a pipeline of products in multiple therapeutic areas. This discovery process integrates multiple technologies, including structural screening as one key component that it hopes will give a significant competitive advantage over other approaches.

In April 2011, Plexxikon was acquired by the Japanese pharmaceutical company Daiichi Sankyo for $805 million and an additional $130 million in potential milestone payments.[1][2][3]

Drug pipeline
  • Plexxikon is collaborating with Wyeth Pharmaceuticals on several products for use in type II diabetes and other metabolic disorders.[4] The most advanced of these agents is indeglitazar (PLX204), which is currently in Phase II clinical trials for type 2 diabetes.[5]
  • PLX7486 is a CSF1R antagonist and pan-TRK inhibitor in clinical trials for advanced solid tumors.[6][7]

References
  1. "Daiichi Sankyo to Acquire Plexxikon".
  2. "Plexxikon acquired by Daiichi Sankyo". Haberman Associates. 2011-03-03. Retrieved 2020-08-06.
  3. "Daiichi Sankyo, Inc. Completes Plexxikon Inc. Acquisition". BioSpace. Retrieved 2020-08-06.
  4. "Wyeth, Plexxikon tie up to develop novel diabetes & metabolic disorders treatment". 28 October 2004. Archived from the original on 24 October 2007.
  5. "Study Evaluating PPM-204 In Subjects With Type 2 Diabetes - Full Text View - ClinicalTrials.gov". Clinical Trials. Retrieved 2020-10-09.
  6. "Fms/Trk tyrosine kinase inhibitor PLX7486". NCI Drug Dictionary. National Cancer Institute.
  7. "Phast 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.